MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success, is developed.
Abstract
Drug development depends on efficacy and safety, but many trial-outcome prediction models incorporate trial design, prior development history or compound identity, enabling compound memorization and inflating apparent performance. We developed MEchanism-Resolved Inference of Trial outcomes (MERIT), a model that predicts trial outcomes from molecular and disease features without using information on similar-compound success. MERIT integrates the disease and drug of interest with large-scale drug-protein, protein-metabolite and immune interaction maps to link a drug’s intended and potential off-target effects to tissue-specific efficacy and safety. Across 753 small-molecule drugs and 3,133 trials, MERIT achieved a best-in-class overall AUROC of 0.770 (0.765 for efficacy and 0.784 for safety). MERIT also recovered the eventual approved indications for 83% of failed drugs. Finally, we registered locked, outcome-blind predictions for 55 drug-indication pairs in ongoing Phase III trials, establishing a prospective evaluation cohort.
A target-centric framework that integrates network medicine principles with target biology features to predict operational target-level labels associated with safety-related drug attrition is proposed and suggests that target biology and interactome context contain signal associated with safety-related clinical attriti...
Jordan Breffle, Alex Jones, S. Ghiassian· Scientific Reports· 0 citations
An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov and may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.
This work develops phase-specific machine learning-based models that support a shift toward feature-resolved, data-driven models in which clinical development success is predicted from the interaction of trial design, sponsor capability, and investigational drug characteristics.
Robert Howard, Beau Bush, Joseph Edelmann et al.· Scientific Reports· 0 citations
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.
This scoping review investigates the current state of PK property prediction of small molecules in drug discovery using machine learning methods and a combination of machine learning and mechanistic models and proposes leveraging the pattern recognition capabilities of deep learning models in conjunction with the biolo...
Lucille Tomin, Vida Bodaghi-Namileh, D. G. Schwartz et al.· Journal of Chemical Informat...· 0 citations
A claim-centered framework is introduced that clarifies which claims current DDI benchmarks can support and what additional evidence is needed before predictions can guide prescribing or monitoring and shows that useful explanations require evidence alignment and actionability in addition to visual plausibility.
Jing-Xiang Yang· Computers and artificial int...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
